{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:03:03Z","timestamp":1792000983166,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Recurrent pericarditis (RP) is a complication (15\u201330%) of acute pericarditis with an unknown etiology. Treatment regimen consists of a combination of non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine, with the addition of corticosteroids in resistant or intolerant cases. In the last decade anakinra was shown as an effective treatment in patients with colchicine resistant and steroid-dependent RP, initially in anecdotal reports in children and more recently in a randomized trial. Canakinumab is a monoclonal antibody selectively blocking IL-1\u03b2 and its use is only anecdotally reported to treat pericarditis. We report two pediatric patients with refractory recurrent pericarditis, who presented an optimal response to anakinra treatment but prompt relapse after switch to canakinumab.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>The first patient is a girl with Recurrent Pericarditis started in April 2015, after heart surgery. NSAIDs and oral steroids were started, with prompt relapse after steroid suspension. The child showed a steroid-dependent RP; anakinra was therefore started with excellent response, but discontinued after 2\u2009weeks for local reactions. In July 2016 therapy with canakinumab was started. She experienced four relapses during canakinumab therapy despite dosage increase and steroid treatment. In January 2018 a procedure of desensitization from anakinra was performed, successfully. Anakinra as monotherapy is currently ongoing, without any sign of flare.<\/jats:p>\n<jats:p>The second patient is a girl with an idiopathic RP, who showed an initial benefit from NSAIDs and colchicine. However, 10 days after the first episode a relapse occurred and therapy with anakinra was established. Two months later, while being in complete remission, anakinra was replaced with canakinumab due to patient\u2019s poor compliance to daily injections. She experienced a relapse requiring steroids 10 days after the first canakinumab injection. Anakinra was subsequently re-started with complete remission, persisting after 24\u2009months follow-up.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We describe two cases of failure of the treatment with anti-IL-1\u03b2 monoclonal antibodies in steroid- dependent idiopathic RP. This anecdotal and preliminary observation suggests a different efficacy of the two IL-1 blockers in the management of RP and support a possible pivotal role of IL-1\u03b1 in the pathogenesis of this condition.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12969-020-00438-5","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T13:03:45Z","timestamp":1592312625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Failure of anti Interleukin-1 \u03b2 monoclonal antibody in the treatment of recurrent pericarditis in two children"],"prefix":"10.1186","volume":"18","author":[{"given":"Sara","family":"Signa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Consolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Miniaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bustaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Tosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Oliveira","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"4","key":"438_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ccl.2017.07.004","volume":"35","author":"M Imazio","year":"2017","unstructured":"Imazio M, Gaita F. Acute and recurrent pericarditis. Cardiol Clin. 2017;35(4):505\u201313. https:\/\/doi.org\/10.1016\/j.ccl.2017.07.004.","journal-title":"Cardiol Clin"},{"issue":"4","key":"438_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11739-018-1842-x","volume":"13","author":"A Brucato","year":"2018","unstructured":"Brucato A, Emmi G, Cantarini L, et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern Emerg Med. 2018;13(4):475\u201389. https:\/\/doi.org\/10.1007\/s11739-018-1842-x.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"438_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"P Picco","year":"2009","unstructured":"Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1\u03b2 receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60(1):264\u20138. https:\/\/doi.org\/10.1002\/art.24174.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"438_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/14779072.2018.1510315","volume":"16","author":"A Galluzzo","year":"2018","unstructured":"Galluzzo A, Imazio M. Advances in medical therapy for pericardial diseases. Expert Rev Cardiovasc Ther. 2018;16(9):635\u201343. https:\/\/doi.org\/10.1080\/14779072.2018.1510315.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"18","key":"438_CR5","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. JAMA. 2016;316(18):1906. https:\/\/doi.org\/10.1001\/jama.2016.15826.","journal-title":"JAMA."},{"key":"438_CR6","doi-asserted-by":"publisher","unstructured":"Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (international registry of Anakinra for pericarditis) study. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319879534.","DOI":"10.1177\/2047487319879534"},{"issue":"8","key":"438_CR7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/rheumatology\/key077","volume":"57","author":"N Kougkas","year":"2018","unstructured":"Kougkas N, Fanouriakis A, Papalopoulos I, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology. 2018;57(8):1494\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/key077.","journal-title":"Rheumatology."},{"issue":"4","key":"438_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1017\/S1047951119000672","volume":"29","author":"S Ep\u00e7a\u00e7an","year":"2019","unstructured":"Ep\u00e7a\u00e7an S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young. 2019;29(4):549\u201351. https:\/\/doi.org\/10.1017\/S1047951119000672.","journal-title":"Cardiol Young"},{"issue":"5","key":"438_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10875-017-0399-1","volume":"37","author":"LO Mendonca","year":"2017","unstructured":"Mendonca LO, Malle L, Donovan FX, et al. Deficiency of Interleukin-1 receptor antagonist (DIRA): report of the first Indian patient and a novel deletion affecting IL1RN. J Clin Immunol. 2017;37(5):445\u201351. https:\/\/doi.org\/10.1007\/s10875-017-0399-1.","journal-title":"J Clin Immunol"},{"issue":"2","key":"438_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.23822\/EurAnnACI.1764-1489.30","volume":"50","author":"TM Yilmaz","year":"2018","unstructured":"Yilmaz TM, Bah\u00e7ecio\u011flu SN. Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction. Eur Ann Allergy Clin Immunol. 2018;50(2):94\u20136. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.30.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"8","key":"438_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ni.3503","volume":"17","author":"NC Di Paolo","year":"2016","unstructured":"Di Paolo NC, Shayakhmetov DM. Interleukin 1\u03b1 and the inflammatory process. Nat Immunol. 2016;17(8):906\u201313. https:\/\/doi.org\/10.1038\/ni.3503.","journal-title":"Nat Immunol"},{"issue":"6","key":"438_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jpeds.2014.01.065","volume":"164","author":"M Finetti","year":"2014","unstructured":"Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (Anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014;164(6):1425\u20131431.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2014.01.065.","journal-title":"J Pediatr"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00438-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-020-00438-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00438-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T23:17:29Z","timestamp":1623799049000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-020-00438-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1186\/s12969-020-00438-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The treatment was approved by IRCCS G.Gaslini Institutional Review Board. Patients legal guardians signed a written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG: Speakers\u2019 fees, consultancies and unrestricted grants from Novartis and Sobi. LOM: speaker\u2019s fees from Novartis and is a recipient of longterm fellowship in autoinflammatory diseases from the European Society of Immunodeficiencies at Giannina Gaslini Institute. The other authors declare that they have no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}